Sugi Predict

Sugi Predict / Compounds / SCHEMBL753300

SCHEMBL753300

SCHEMBL753300

CCCCCCCC/C=C\CCCCCCCC(=O)O[C@@H](CO)COP(=O)([O-])OCC[N+](C)(C)C

nearest known ligand 0.76

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ ALDH1A1 P00352 1/20 0.76
▸ SMN1; SMN2 Q16637 1/20 0.73
▸ NR5A2 O00482 1/20 0.73
▸ NR5A1 Q13285 1/20 0.73
▸ RECQL P46063 1/20 0.68
▸ MAPT P10636 1/20 0.64
▸ S1PR1 P21453 2/20 0.63
▸ PRKCA P17252 2/20 0.59
▸ PRKCE Q02156 1/20 0.59
▸ PRKCQ Q04759 1/20 0.59
▸ PRKCD Q05655 1/20 0.59
▸ DAGLA Q9Y4D2 1/20 0.58
▸ ADRA1D P25100 1/20 0.58
▸ PTAFR P25105 1/20 0.58
▸ HTR1D P28221 1/20 0.58
▸ HTR2C P28335 1/20 0.58
▸ ADRA1B P35368 1/20 0.58
▸ DRD3 P35462 1/20 0.58
▸ TMEM97 Q5BJF2 1/20 0.58
▸ MEN1 O00255 1/20 0.57

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29410678 1.00 ALDH1A1 (0.76) ALDH1A1SMN1; SMN2NR5A2NR5A1RECQL
SCHEMBL30652061 1.00 ALDH1A1 (0.76) ALDH1A1SMN1; SMN2NR5A2NR5A1RECQL
SCHEMBL3406499 1.00 ALDH1A1 (0.76) ALDH1A1SMN1; SMN2NR5A2NR5A1RECQL
SCHEMBL3403745 1.00 ALDH1A1 (0.76) ALDH1A1SMN1; SMN2NR5A2NR5A1RECQL
SCHEMBL3410573 1.00 ALDH1A1 (0.76) ALDH1A1SMN1; SMN2NR5A2NR5A1RECQL
SCHEMBL3406019 1.00 ALDH1A1 (0.76) ALDH1A1SMN1; SMN2NR5A2NR5A1RECQL
SCHEMBL3407855 1.00 ALDH1A1 (0.76) ALDH1A1SMN1; SMN2NR5A2NR5A1RECQL
SCHEMBL3405833 1.00 ALDH1A1 (0.76) ALDH1A1SMN1; SMN2NR5A2NR5A1RECQL
SCHEMBL5053766 1.00 ALDH1A1 (0.76) ALDH1A1SMN1; SMN2NR5A2NR5A1RECQL
SCHEMBL30521870 1.00 ALDH1A1 (0.76) ALDH1A1SMN1; SMN2NR5A2NR5A1RECQL

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 58 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4540387-A2 LIPID NANOPARTICLES (LNPS)-BASED OCULAR DELIVERY CRISPR Therapeutics AG (CH) 2025-04-23 — — EP claimed
US-12226740-B2 Stabilized filtration device RETEIN AB (SE) 2025-02-18 — — US claimed
WO-2024094211-A1 LIPID COMPOSITION 斯微(上海)生物科技股份有限公司 2024-05-10 — — WO claimed
WO-2023242827-A2 LIPID NANOPARTICLES (LNPs)-BASED OCULAR DELIVERY CRISPR THERAPEUTICS AG (CH) 2023-12-21 — — WO claimed
WO-2023015901-A1 NOVEL CATIONIC LIPID COMPOUND 广州谷森制药有限公司 2023-02-16 — — WO claimed
US-20220152559-A1 STABILIZED FILTRATION DEVICE RETEIN AB (SE) 2022-05-19 — — US claimed
EP-3930884-A1 STABILIZED FILTRATION DEVICE Aquammodate AB (SE) 2022-01-05 — — EP claimed
CN-113453791-A Stabilized filter device 海纳有限公司 2021-09-28 — — CN claimed
US-20080160313-A1 Lipid bilayers on nanotextured solid surfaces ENERGY, U.S. DEPARTMENT OF 2008-07-03 — — US claimed
EP-4695385-A1 GENE EDITING FOR INTERVERTEBRAL, INTRA- AND PERIDISCAL THERAPY AND ASSOCIATED SPINAL DISORDERS Orthobio Therapeutics, Inc. (US) 2026-02-18 — — EP disclosed
WO-2025088570-A1 IONIZABLE LIPIDS AND IONIZABLE LIPID NANOPARTICLES CRISPR THERAPEUTICS AG (CH) 2025-05-01 — — WO disclosed
US-12263181-B2 Phospholipid compositions MACHAVERT PHARMACEUTICALS LLC (US) 2025-04-01 — — US disclosed
US-12226740-B2 Stabilized filtration device RETEIN AB (SE) 2025-02-18 — — US disclosed
WO-2024215956-A1 GENE EDITING FOR INTERVERTEBRAL, INTRA-AND PERIDISCAL THERAPY AND ASSOCIATED SPINAL DISORDERS ORTHOBIO THERAPEUTICS, INC. (US) 2024-10-17 — — WO disclosed
US-20060009469-A1 Particulate-stabilized injectable pharmacutical compositions of posaconazole SCHERING CORPORATION 2006-01-12 — — US disclosed
WO-2005020929-A2 SUSTAINED RELEASE DOSAGE FORMS OF ZIPRASIDONE AHMED IMRAN (US) 2005-03-10 — — WO disclosed
EP-0161519-B1 DERIVATIVES OF GLYCEROPHOSPHOCHOLINE AND OF GLYCEROPHOSPHOETHANOL AMINE, THEIR PREPARATION AND USE CHEMIE LINZ AKTIENGESELLSCHAFT (AT) 1988-06-29 — — EP disclosed
US-4717512-A Preparation of acylated glycerophosphocholines and glycerophosphoethanolamines CHEMIE LINZ AKTIENGESELLSCHAFT (AT) 1988-01-05 — — US disclosed
US-4622180-A Derivatives of glycerophosphocholine and glycerophosphoethanolamine, their preparation and their use CHEMIE LINZ AKTIENGESELLSCHAFT (AT) 1986-11-11 — — US disclosed
EP-0161519-A2 Derivatives of glycerophosphocholine and of glycerophosphoethanol amine, their preparation and use CHEMIE LINZ AKTIENGESELLSCHAFT (AT) 1985-11-21 — — EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060009469-A1 Particulate-stabilized injectable pharmacutical compositions of posaconazole STS, ERG28, PRPF19 ALDH1A1 1932/4885SMN1; SMN2 3177/4885NR5A2 2050/4885
US-12263181-B2 Phospholipid compositions PHOSPHO1, SGMS1, SGMS2 ALDH1A1 4849/4885SMN1; SMN2 1802/4885NR5A2 4657/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.